Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on July 30, 2019. The registrant is a Delaware corporation focused on regenerative medicine. The report addresses corporate governance changes effective as of July 30, 2019, and August 5, 2019.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a new director and the associated compensatory arrangements.
Material Changes
- Board Resignation: Michael Mulroy resigned from the Board of Directors on July 30, 2019. The resignation was not due to any disagreement with the company regarding operations, policies, or practices.
- Board Appointment: Michael H. May was appointed to the Board of Directors on August 5, 2019, to fill the vacancy left by Mr. Mulroy.
- Committee Assignments: Dr. May will serve on the Audit Committee and the Nominating & Corporate Governance Committee.
Guidance, Outlook, and Management Commentary
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors. There is no specific business outlook, guidance, or discussion of contingencies related to operations or financial performance in this report.
Compensatory Arrangements for Dr. May:
- Stock Options: Granted options to purchase 26,534 shares of common stock under the 2017 Equity Incentive Plan.
- Cash Fee: A cash fee of $14,288 for service as a director for the remainder of the calendar year.
- Vesting Schedule: Both the options and cash fee vest/pay in two equal fiscal quarterly installments, contingent on Dr. May remaining a director on the last day of the applicable fiscal quarter.
Investor Verification Checklist
- Verify the qualifications and potential conflicts of interest of the new director, Dr. Michael H. May, particularly regarding his role at CCRM Enterprises and Rimon Therapeutics.
- Confirm the total number of outstanding stock options and the dilution impact of the 26,534 options granted to Dr. May.
- Review the company's most recent periodic reports (10-K or 10-Q) for financial health, as this 8-K contains no financial data.
- Monitor future filings to ensure the resignation of Mr. Mulroy does not signal broader governance instability.